22 related articles for article (PubMed ID: 22749422)
1. Identifying structural features on 1,1-diphenyl-hexahydro-oxazolo[3,4-a]pyrazin-3-ones critical for Neuropeptide S antagonist activity.
Zhang Y; Gilmour BP; Navarro HA; Runyon SP
Bioorg Med Chem Lett; 2008 Jul; 18(14):4064-7. PubMed ID: 18555684
[TBL] [Abstract][Full Text] [Related]
2. Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties.
Amin KM; El-Badry OM; Abdel Rahman DE; Abdellattif MH; Abourehab MAS; El-Maghrabey MH; Elsaid FG; El Hamd MA; Elkamhawy A; Ammar UM
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145702
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.
Dzierba CD; Takvorian AG; Rafalski M; Kasireddy-Polam P; Wong H; Molski TF; Zhang G; Li YW; Lelas S; Peng Y; McElroy JF; Zaczek RC; Taub RA; Combs AP; Gilligan PJ; Trainor GL
J Med Chem; 2004 Nov; 47(23):5783-90. PubMed ID: 15509177
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
Saito T; Obitsu T; Kohno H; Sugimoto I; Matsushita T; Nishiyama T; Hirota T; Takeda H; Matsumura N; Ueno S; Kishi A; Kagamiishi Y; Nakai H; Takaoka Y
Bioorg Med Chem; 2012 Jan; 20(2):1122-38. PubMed ID: 22196514
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE
J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.
Han X; Michne JA; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Dubowchik GM
Bioorg Med Chem Lett; 2005 Sep; 15(17):3870-3. PubMed ID: 15990298
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA; Ahuja VT; Schmitz WD; Molski TF; Mattson GK; Lodge NJ; Bronson JJ; Macor JE
Bioorg Med Chem Lett; 2010 Mar; 20(6):1890-4. PubMed ID: 20176478
[TBL] [Abstract][Full Text] [Related]
8. Small molecule antagonists of the corticotropin releasing factor (CRF) receptor: recent medicinal chemistry developments.
Tellew JE; Luo Z
Curr Top Med Chem; 2008; 8(6):506-20. PubMed ID: 18397172
[TBL] [Abstract][Full Text] [Related]
9. Antagonists of the corticotropin releasing factor receptor.
Saunders J; Williams J
Prog Med Chem; 2003; 41():195-247. PubMed ID: 12774695
[No Abstract] [Full Text] [Related]
10. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders.
Grigoriadis DE
Expert Opin Ther Targets; 2005 Aug; 9(4):651-84. PubMed ID: 16083336
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists.
Dzierba CD; Sielecki TM; Arvanitis AG; Galka A; Johnson TL; Takvorian AG; Rafalski M; Kasireddy-Polam P; Vig S; Dasgupta B; Zhang G; Molski TF; Wong H; Zaczek RC; Lodge NJ; Combs AP; Gilligan PJ; Trainor GL; Bronson JJ; Macor JE
Bioorg Med Chem Lett; 2012 Aug; 22(15):4986-9. PubMed ID: 22749422
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
